Daxor Corporation to Exhibit at the 22nd Annual Scientific Meeting of the Heart Failure Society of America
September 12 2018 - 8:30AM
Daxor Corporation (NYSE MKT: DXR)
an investment company with innovative medical instrumentation and
biotechnology operations focused on blood volume measurement today
announces it will be attending the 22nd Annual Scientific Meeting
of the Heart Failure Society of America (HFSA) at the Gaylord
Opryland Hotel and Convention Center in Nashville, TN from
September 15-17th, 2018.
“The HFSA’s Annual Scientific Meeting is a
premier event that gathers the best scientific minds focused on
heart failure research and outcomes. We are looking forward to
sharing with leaders in the field how our BVA technology has been
shown to reduce heart failure readmissions by 56% and mortality by
over 80%,” said Michael Feldschuh, CEO of Daxor Corporation. The
company will be exhibiting at Booth #210.
About Daxor Corporation
Daxor Corporation is an innovative medical
instrumentation and biotechnology company. We manufacture the
BVA-100 Blood Volume Analyzer, the first instrument approved by the
FDA to provide rapid direct measurement of a patient’s blood
volume. We believe that the BVA-100 Blood Volume Analyzer has the
potential to transform therapy in a broad range of surgical and
medical conditions. It is our goal, working in conjunction with
hospitals and clinics, to achieve that possibility. Ultimately the
company’s mission is to help hospitals and physicians incorporate
Daxor’s BVA-100 diagnostic to significantly improve the quality of
patient care. For more information please visit our website at
http://www.daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Daxor Corporation:
Soren Thompson
Investor Relations
212-330-8502
sthompson@daxor.com
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner
CORE IR
561-479-8566
brets@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
juleas@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024